GSK Announces £400 Million Expansion of Stevenage R&D Facility to Create Leading Life Sciences Cluster

Compiled and Translated by | Tom Li

Recently, GlaxoSmithKline (GSK) announced plans to expand its existing 92-acre R&D site in Stevenage, England, aiming to transform it into one of Europe's largest biotechnology and life sciences company "clusters".

Currently, GlaxoSmithKline has officially begun seeking a development partner for its expansion plan. As part of the proposal, which involves up to £400 million in new investment to construct a new campus, GlaxoSmithKline expects to select a private-sector developer and sell 33 acres of land later this year. The UK-based pharmaceutical company added in a statement that the site expansion could also create up to 5,000 highly skilled jobs over the next five years.

Supported by the UK government, the project is expected to commence master planning for the new campus in 2022, providing an additional 100,000 square meters of floor space for commercial life sciences research and development. Stevenage is home to one of GSK's two global research and development centres and hosts the UK's largest cell and gene therapy cluster. The detailed expansion plan was jointly developed by the Stevenage Bioscience Catalyst (SBC), the UK government, Stevenage Borough Council, and the Local Enterprise Partnership (LEP).

Last month, GlaxoSmithKline announced its 10-year strategy, with CEO Emma Walmsley revealing that the company expects product sales to reach £33 billion ($46 billion) by 2031. Walmsley is therefore facing mounting pressure to significantly boost GlaxoSmithKline's performance before the planned split of its consumer health and biopharmaceutical divisions, a process that is currently underway.

Earlier this year, reports indicated that after activist hedge fund Elliott Management acquired a substantial stake in GlaxoSmithKline (GSK), rumors even emerged that the company might be put up for sale. Elliott has expressed skepticism regarding whether CEO Emma Walmsley is capable of steering the company's future development.

Elliott argues that despite Walmsley's 17 years of experience at GSK, it does not align with the capabilities required to lead a biopharmaceutical company. Furthermore, Elliott has criticized Walmsley for a lack of consistency in strategic direction. For instance, the company sold its oncology business to Novartis in 2015, only to re-enter the oncology sector in 2018 by acquiring Tesaro for $5 billion.

Source: GSK reveals plans for £400m R&D facility expansion in England